- 抑制剂
- 化合物库
- 抗体
- 生物试剂
- qPCR
- 2x SYBR Green qPCR Master Mix
- 2x SYBR Green qPCR Master Mix(Low ROX)
- 2x SYBR Green qPCR Master Mix(High ROX)
- 蛋白实验
- Protein A/G免疫沉淀磁珠
- Anti-DYKDDDDK Tag免疫磁珠
- Anti-DYKDDDDK Tag亲和凝胶
- Anti-Myc免疫磁珠
- Anti-HA免疫磁珠
- 磁力架
- Poly DYKDDDDK Tag多肽
- 细胞核与细胞浆蛋白抽提试剂盒
- 免疫磁珠
- 蛋白酶抑制剂Cocktail
- 蛋白酶抑制剂Cocktail(DMSO储液)
- 磷酸酶抑制剂Cocktail
- 新产品
- 联系我们
GSK269962A HCl
别名: GSK269962B, GSK269962
GSK269962A HCl是选择性的ROCK(Rho-associated protein kinase)抑制剂，对ROCK1和ROCK2的IC50分别为1.6 nM和4 nM。
GSK269962A HCl Chemical Structure
CAS: 2095432-71-4
GSK269962A HCl相关产品
相关信号通路图
细胞实验数据示例
| 细胞系 | 实验类型 | 给药浓度 | 孵育时间 | 活性描述 | 文献信息(PMID) |
|---|---|---|---|---|---|
| NCI-H1581 | Growth inhibition assay | Inhibition of human NCI-H1581 cell growth in a cell viability assay, IC50=18.8477 μM | SANGER | ||
| NCI-H1694 | Growth inhibition assay | Inhibition of human NCI-H1694 cell growth in a cell viability assay, IC50=24.8749 μM | SANGER | ||
| NCI-H1963 | Growth inhibition assay | Inhibition of human NCI-H1963 cell growth in a cell viability assay, IC50=1.27839 μM | SANGER | ||
| NCI-H2081 | Growth inhibition assay | Inhibition of human NCI-H2081 cell growth in a cell viability assay, IC50=34.6044 μM | SANGER | ||
| NCI-H209 | Growth inhibition assay | Inhibition of human NCI-H209 cell growth in a cell viability assay, IC50=22.6272 μM | SANGER | ||
| NCI-H2107 | Growth inhibition assay | Inhibition of human NCI-H2107 cell growth in a cell viability assay, IC50=25.6561 μM | SANGER | ||
| NCI-H2126 | Growth inhibition assay | Inhibition of human NCI-H2126 cell growth in a cell viability assay, IC50=6.50426 μM | SANGER | ||
| NCI-H2171 | Growth inhibition assay | Inhibition of human NCI-H2171 cell growth in a cell viability assay, IC50=0.95937 μM | SANGER | ||
| NCI-H2227 | Growth inhibition assay | Inhibition of human NCI-H2227 cell growth in a cell viability assay, IC50=7.88616 μM | SANGER | ||
| NCI-H524 | Growth inhibition assay | Inhibition of human NCI-H524 cell growth in a cell viability assay, IC50=22.8763 μM | SANGER | ||
| NCI-H526 | Growth inhibition assay | Inhibition of human NCI-H526 cell growth in a cell viability assay, IC50=18.5431 μM | SANGER | ||
| NCI-H720 | Growth inhibition assay | Inhibition of human NCI-H720 cell growth in a cell viability assay, IC50=2.45161 μM | SANGER | ||
| NMC-G1 | Growth inhibition assay | Inhibition of human NMC-G1 cell growth in a cell viability assay, IC50=15.0578 μM | SANGER | ||
| NOS-1 cell | Growth inhibition assay | Inhibition of human NOS-1 cell growth in a cell viability assay, IC50=5.82294 μM | SANGER | ||
| OCI-AML2 cell | Growth inhibition assay | Inhibition of human OCI-AML2 cell growth in a cell viability assay, IC50=10.9496 μM | SANGER | ||
| OCUB-M cell | Growth inhibition assay | Inhibition of human OCUB-M cell growth in a cell viability assay, IC50=17.201 μM | SANGER | ||
| ONS-76 cell | Growth inhibition assay | Inhibition of human ONS-76 cell growth in a cell viability assay, IC50=13.9191 μM | SANGER | ||
| OS-RC-2 cell | Growth inhibition assay | Inhibition of human OS-RC-2 cell growth in a cell viability assay, IC50=46.195 μM | SANGER | ||
| OVCAR-4 cell | Growth inhibition assay | Inhibition of human OVCAR-4 cell growth in a cell viability assay, IC50=8.71808 μM | SANGER | ||
| P30-OHK cell | Growth inhibition assay | Inhibition of human P30-OHK cell growth in a cell viability assay, IC50=7.62877 μM | SANGER | ||
| P30-OHK cell | Growth inhibition assay | Inhibition of human PF-382 cell growth in a cell viability assay, IC50=7.04954 μM | SANGER | ||
| PSN1 cell | Growth inhibition assay | Inhibition of human PSN1 cell growth in a cell viability assay, IC50=6.22126 μM | SANGER | ||
| QIMR-WIL cell | Growth inhibition assay | Inhibition of human QIMR-WIL cell growth in a cell viability assay, IC50=0.49004 μM | SANGER | ||
| RCC10RGB cell | Growth inhibition assay | Inhibition of human RCC10RGB cell growth in a cell viability assay, IC50=18.9036 μM | SANGER | ||
| RKO cell | Growth inhibition assay | Inhibition of human RKO cell growth in a cell viability assay, IC50=10.5662 μM | SANGER | ||
| RL95-2 cell | Growth inhibition assay | Inhibition of human RL95-2 cell growth in a cell viability assay, IC50=10.67 μM | SANGER | ||
| RPMI-6666 cell | Growth inhibition assay | Inhibition of human RPMI-6666 cell growth in a cell viability assay, IC50=18.5236 μM | SANGER | ||
| RPMI-8402 cell | Growth inhibition assay | Inhibition of human RPMI-8402 cell growth in a cell viability assay, IC50=4.5856 μM | SANGER | ||
| RXF393 cell | Growth inhibition assay | Inhibition of human RXF393 cell growth in a cell viability assay, IC50=0.393 μM | SANGER | ||
| Ramos-2G6-4C10 cell | Growth inhibition assay | Inhibition of human Ramos-2G6-4C10 cell growth in a cell viability assay, IC50=1.357 μM | SANGER | ||
| SCLC-21H cell | Growth inhibition assay | Inhibition of human SCLC-21H cell growth in a cell viability assay, IC50=7.61149 μM | SANGER | ||
| SF126 cell | Growth inhibition assay | Inhibition of human SF126 cell growth in a cell viability assay, IC50=11.8321μM | SANGER | ||
| SF268 cell | Growth inhibition assay | Inhibition of human SF268 cell growth in a cell viability assay, IC50=6.23183 μM | SANGER | ||
| SF539 cell | Growth inhibition assay | Inhibition of human SF539 cell growth in a cell viability assay, IC50=1.28661 μM | SANGER | ||
| SH-4 cell | Growth inhibition assay | Inhibition of human SH-4 cell growth in a cell viability assay, IC50=5.75508 μM | SANGER | ||
| SIG-M5 cell | Growth inhibition assay | Inhibition of human SIG-M5 cell growth in a cell viability assay, IC50=11.7259 μM | SANGER | ||
| SJSA-1 cell | Growth inhibition assay | Inhibition of human SJSA-1 cell growth in a cell viability assay, IC50=1.04526 μM | SANGER | ||
| SK-LMS-1 cell | Growth inhibition assay | Inhibition of human SK-LMS-1 cell growth in a cell viability assay, IC50=32.5965 μM | SANGER | ||
| SK-MM-2 cell | Growth inhibition assay | Inhibition of human SK-MM-2 cell growth in a cell viability assay, IC50=42.3405 μM | SANGER | ||
| SK-N-DZ cell | Growth inhibition assay | Inhibition of human SK-N-DZ cell growth in a cell viability assay, IC50=9.48314 μM | SANGER | ||
| SK-NEP-1 cell | Growth inhibition assay | Inhibition of human SK-NEP-1 cell growth in a cell viability assay, IC50=17.5456 μM | SANGER | ||
| SK-PN-DW cell | Growth inhibition assay | Inhibition of human SK-PN-DW cell growth in a cell viability assay, IC50=24.9736 μM | SANGER | ||
| SNB75 cell | Growth inhibition assay | Inhibition of human SNB75 cell growth in a cell viability assay, IC50=8.07737 μM | SANGER | ||
| SR cell | Growth inhibition assay | Inhibition of human SR cell growth in a cell viability assay, IC50=0.000137 μM | SANGER | ||
| SU-DHL-1 cell | Growth inhibition assay | Inhibition of human SU-DHL-1 cell growth in a cell viability assay, IC50=12.7336 μM | SANGER | ||
| SW684 cell | Growth inhibition assay | Inhibition of human SW684 cell growth in a cell viability assay, IC50=39.011 μM | SANGER | ||
| SW872 cell | Growth inhibition assay | Inhibition of human SW872 cell growth in a cell viability assay, IC50=0.88656 μM | SANGER | ||
| SW962 cell | Growth inhibition assay | Inhibition of human SW962 cell growth in a cell viability assay, IC50=12.7521 μM | SANGER | ||
| 697 cell | Growth inhibition assay | Inhibition of human 697 cell growth in a cell viability assay, IC50=0.2991 μM | SANGER | ||
| 8-MG-BA cell | Growth inhibition assay | Inhibition of human 8-MG-BA cell growth in a cell viability assay, IC50=23.0793 μM | SANGER | ||
| A101D cell | Growth inhibition assay | Inhibition of human A101D cell growth in a cell viability assay, IC50=1.87034 μM | SANGER | ||
| ACN cell | Growth inhibition assay | Inhibition of human ACN cell growth in a cell viability assay, IC50=21.4387 μM | SANGER | ||
| AM-38 cell | Growth inhibition assay | Inhibition of human AM-38 cell growth in a cell viability assay, IC50=7.26327 μM | SANGER | ||
| ATN-1 cell | Growth inhibition assay | Inhibition of human ATN-1 cell growth in a cell viability assay, IC50=24.7555 μM | SANGER | ||
| BB30-HNC cell | Growth inhibition assay | Inhibition of human BB30-HNC cell growth in a cell viability assay, IC50=22.2532 μM | SANGER | ||
| BB49-HNC cell | Growth inhibition assay | Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50=0.00789 μM | SANGER | ||
| human BC-1 cell | Growth inhibition assay | Inhibition of human BC-1 cell growth in a cell viability assay, IC50=3.97107 μM | SANGER | ||
| BE-13 cell | Growth inhibition assay | Inhibition of human BE-13 cell growth in a cell viability assay, IC50=0.14081μM | SANGER | ||
| BL-70 cell | Growth inhibition assay | Inhibition of human BL-70 cell growth in a cell viability assay, IC50=3.40703 μM | SANGER | ||
| BV-173 cell | Growth inhibition assay | Inhibition of human BV-173 cell growth in a cell viability assay, IC50=18.8859 μM | SANGER | ||
| Becker cell | Growth inhibition assay | Inhibition of human Becker cell growth in a cell viability assay, IC50=13.9545 μM | SANGER | ||
| CAL-148 cell | Growth inhibition assay | Inhibition of human CAL-148 cell growth in a cell viability assay, IC50=35.6557 μM | SANGER | ||
| TE-10 cell | Growth inhibition assay | Inhibition of human TE-10 cell growth in a cell viability assay, IC50=22.8423 μM | SANGER | ||
| TE-12 cell | Growth inhibition assay | Inhibition of human TE-12 cell growth in a cell viability assay, IC50=32.4114 μM | SANGER | ||
| TE-8 cell | Growth inhibition assay | Inhibition of human TE-8 cell growth in a cell viability assay, IC50=11.6089 μM | SANGER | ||
| TE-9 cell | Growth inhibition assay | Inhibition of human TE-9 cell growth in a cell viability assay, IC50=36.6381 μM | SANGER | ||
| TGW cell | Growth inhibition assay | Inhibition of human TGW cell growth in a cell viability assay, IC50=23.3577 μM | SANGER | ||
| UACC-257 cell | Growth inhibition assay | Inhibition of human UACC-257 cell growth in a cell viability assay, IC50=8.70625 μM | SANGER | ||
| WSU-NHL cell | Growth inhibition assay | Inhibition of human WSU-NHL cell growth in a cell viability assay, IC50=27.1907 μM | SANGER | ||
| no-10 cell | Growth inhibition assay | Inhibition of human no-10 cell growth in a cell viability assay, IC50=0.66846 μM | SANGER | ||
| no-11 cell | Growth inhibition assay | Inhibition of human no-11 cell growth in a cell viability assay, IC50=47.0263 μM | SANGER | ||
| CAS-1 cell | Growth inhibition assay | Inhibition of human CAS-1 cell growth in a cell viability assay, IC50=0.847 μM | SANGER | ||
| CCRF-CEM cell | Growth inhibition assay | Inhibition of human CCRF-CEM cell growth in a cell viability assay, IC50=8.65392 μM | SANGER | ||
| CMK cell | Growth inhibition assay | Inhibition of human CMK cell growth in a cell viability assay, IC50=1.01323 μM | SANGER | ||
| COLO-829 cell | Growth inhibition assay | Inhibition of human COLO-829 cell growth in a cell viability assay, IC50=3.24226 μM | SANGER | ||
| COR-L279 cell | Growth inhibition assay | Inhibition of human COR-L279 cell growth in a cell viability assay, IC50=2.0738 μM | SANGER | ||
| CP66-MEL cell | Growth inhibition assay | Inhibition of human CP66-MEL cell growth in a cell viability assay, IC50=36.5497 μM | SANGER | ||
| CRO-AP2 cell | Growth inhibition assay | Inhibition of human CRO-AP2 cell growth in a cell viability assay, IC50=2.36088 μM | SANGER | ||
| CTV-1 cell | Growth inhibition assay | Inhibition of human CTV-1 cell growth in a cell viability assay, IC50=23.9145 μM | SANGER | ||
| Calu-6 cell | Growth inhibition assay | Inhibition of human Calu-6 cell growth in a cell viability assay, IC50=47.586 μM | SANGER | ||
| D-247MG cell | Growth inhibition assay | Inhibition of human D-247MG cell growth in a cell viability assay, IC50=0.62814 μM | SANGER | ||
| D-263MG cell | Growth inhibition assay | Inhibition of human D-263MG cell growth in a cell viability assay, IC50=0.08509 μM | SANGER | ||
| D-336MG cell | Growth inhibition assay | Inhibition of human D-336MG cell growth in a cell viability assay, IC50=0.62854 μM | SANGER | ||
| D-392MG cell | Growth inhibition assay | Inhibition of human D-392MG cell growth in a cell viability assay, IC50=1.43039 μM | SANGER | ||
| D-502MG cell | Growth inhibition assay | Inhibition of human D-502MG cell growth in a cell viability assay, IC50=8.53492 μM | SANGER | ||
| D-542MG cell | Growth inhibition assay | Inhibition of human D-542MG cell growth in a cell viability assay, IC50=12.3152 μM | SANGER | ||
| DB cell | Growth inhibition assay | Inhibition of human DB cell growth in a cell viability assay, IC50=47.1417 μM | SANGER | ||
| DEL cell | Growth inhibition assay | Inhibition of human DEL cell growth in a cell viability assay, IC50=7.01898 μM | SANGER | ||
| DMS-114 cell | Growth inhibition assay | Inhibition of human DMS-114 cell growth in a cell viability assay, IC50=49.8468 μM | SANGER | ||
| DMS-153 cell | Growth inhibition assay | Inhibition of human DMS-153 cell growth in a cell viability assay, IC50=42.9923 μM | SANGER | ||
| DOHH-2 cell | Growth inhibition assay | Inhibition of human DOHH-2 cell growth in a cell viability assay, IC50=4.22764 μM | SANGER | ||
| DSH1 cell | Growth inhibition assay | Inhibition of human DSH1 cell growth in a cell viability assay, IC50=8.43623 μM | SANGER | ||
| Daudi cell | Growth inhibition assay | Inhibition of human Daudi cell growth in a cell viability assay, IC50=2.09802 μM | SANGER | ||
| EC-GI-10 cell | Growth inhibition assay | Inhibition of human EC-GI-10 cell growth in a cell viability assay, IC50=44.2589 μM | SANGER | ||
| ECC4 cell | Growth inhibition assay | Inhibition of human ECC4 cell growth in a cell viability assay, IC50=32.1896 μM | SANGER | ||
| EM-2 cell | Growth inhibition assay | Inhibition of human EM-2 cell growth in a cell viability assay, IC50=2.45594 μM | SANGER | ||
| ES1 cell | Growth inhibition assay | Inhibition of human ES1 cell growth in a cell viability assay, IC50=5.54087 μM | SANGER | ||
| ES3 cell | Growth inhibition assay | Inhibition of human ES3 cell growth in a cell viability assay, IC50=42.4729 μM | SANGER | ||
| ES4 cell | Growth inhibition assay | Inhibition of human ES4 cell growth in a cell viability assay, IC50=35.195 μM | SANGER | ||
| ES6 cell | Growth inhibition assay | Inhibition of human ES6 cell growth in a cell viability assay, IC50=0.24733 μM | SANGER | ||
| ES7 cell | Growth inhibition assay | Inhibition of human ES7 cell growth in a cell viability assay, IC50=5.23124 μM | SANGER | ||
| ES8 cell | Growth inhibition assay | Inhibition of human ES8 cell growth in a cell viability assay, IC50=0.81924 μM | SANGER | ||
| EW-18 cell | Growth inhibition assay | Inhibition of human EW-18 cell growth in a cell viability assay, IC50=13.6759 μM | SANGER | ||
| EW-22 cell | Growth inhibition assay | Inhibition of human EW-22 cell growth in a cell viability assay, IC50=47.7947 μM | SANGER | ||
| GCIY cell | Growth inhibition assay | Inhibition of human GCIY cell growth in a cell viability assay, IC50=9.80389 μM | SANGER | ||
| GDM-1 cell | Growth inhibition assay | Inhibition of human GDM-1 cell growth in a cell viability assay, IC50=8.39196 μM | SANGER | ||
| GI-1 cell | Growth inhibition assay | Inhibition of human GI-1 cell growth in a cell viability assay, IC50=0.00523 μM | SANGER | ||
| GI-ME-N cell | Growth inhibition assay | Inhibition of human GI-ME-N cell growth in a cell viability assay, IC50=0.04951 μM | SANGER | ||
| GR-ST cell | Growth inhibition assay | Inhibition of human GR-ST cell growth in a cell viability assay, IC50=13.7902 μM | SANGER | ||
| GT3TKB cell | Growth inhibition assay | Inhibition of human GT3TKB cell growth in a cell viability assay, IC50=1.60389 μM | SANGER | ||
| HAL-01 cell | Growth inhibition assay | Inhibition of human HAL-01 cell growth in a cell viability assay, IC50=6.69712 μM | SANGER | ||
| HCC1599 cell | Growth inhibition assay | Inhibition of human HCC1599 cell growth in a cell viability assay, IC50=37.6011 μM | SANGER | ||
| HCC2218 cell | Growth inhibition assay | Inhibition of human HCC2218 cell growth in a cell viability assay, IC50=13.3834 μM | SANGER | ||
| HD-MY-Z cell | Growth inhibition assay | Inhibition of human HD-MY-Z cell growth in a cell viability assay, IC50=25.2146 μM | SANGER | ||
| HL-60 cell | Growth inhibition assay | Inhibition of human HL-60 cell growth in a cell viability assay, IC50=12.2114 μM | SANGER | ||
| HOP-62 cell | Growth inhibition assay | Inhibition of human HOP-62 cell growth in a cell viability assay, IC50=23.9527 μM | SANGER | ||
| HT cell | Growth inhibition assay | Inhibition of human HT cell growth in a cell viability assay, IC50=4.44321 μM | SANGER | ||
| HT-144 cell | Growth inhibition assay | Inhibition of human HT-144 cell growth in a cell viability assay, IC50=4.90686 μM | SANGER | ||
| HUTU-80 cell | Growth inhibition assay | Inhibition of human HUTU-80 cell growth in a cell viability assay, IC50=3.78986 μM | SANGER | ||
| IST-MEL1 cell | Growth inhibition assay | Inhibition of human IST-MEL1 cell growth in a cell viability assay, IC50=32.9086 μM | SANGER | ||
| IST-SL1 cell | Growth inhibition assay | Inhibition of human IST-SL1 cell growth in a cell viability assay, IC50=2.17079 μM | SANGER | ||
| IST-SL2 cell | Growth inhibition assay | Inhibition of human IST-SL2 cell growth in a cell viability assay, IC50=3.26608 μM | SANGER | ||
| K052 cell | Growth inhibition assay | Inhibition of human K052 cell growth in a cell viability assay, IC50=0.75301 μM | SANGER | ||
| K5 cell | Growth inhibition assay | Inhibition of human K5 cell growth in a cell viability assay, IC50=33.5915 μM | SANGER | ||
| KALS-1 cell | Growth inhibition assay | Inhibition of human KALS-1 cell growth in a cell viability assay, IC50=29.3969 μM | SANGER | ||
| KARPAS-422 cell | Growth inhibition assay | Inhibition of human KARPAS-422 cell growth in a cell viability assay, IC50=42.9142 μM | SANGER | ||
| KARPAS-45 cell | Growth inhibition assay | Inhibition of human KARPAS-45 cell growth in a cell viability assay, IC50=4.11247 μM | SANGER | ||
| KE-37 cell | Growth inhibition assay | Inhibition of human KE-37 cell growth in a cell viability assay, IC50=9.835 μM | SANGER | ||
| KG-1 cell | Growth inhibition assay | Inhibition of human KG-1 cell growth in a cell viability assay, IC50=23.9757 μM | SANGER | ||
| KGN cell | Growth inhibition assay | Inhibition of human KGN cell growth in a cell viability assay, IC50=0.56742 μM | SANGER | ||
| KM12 cell | Growth inhibition assay | Inhibition of human KM12 cell growth in a cell viability assay, IC50=3.52964 μM | SANGER | ||
| KMOE-2 cell | Growth inhibition assay | Inhibition of human KMOE-2 cell growth in a cell viability assay, IC50=30.4549 μM | SANGER | ||
| KNS-42 cell | Growth inhibition assay | Inhibition of human KNS-42 cell growth in a cell viability assay, IC50=8.81915 μM | SANGER | ||
| KNS-81-FD cell | Growth inhibition assay | Inhibition of human KNS-81-FD cell growth in a cell viability assay, IC50=37.426 μM | SANGER | ||
| KS-1 cell | Growth inhibition assay | Inhibition of human KS-1 cell growth in a cell viability assay, IC50=0.0046 μM | SANGER | ||
| KU812 cell | Growth inhibition assay | Inhibition of human KU812 cell growth in a cell viability assay, IC50=23.484 μM | SANGER | ||
| L-540 cell | Growth inhibition assay | Inhibition of human L-540 cell growth in a cell viability assay, IC50=20.7445 μM | SANGER | ||
| LAMA-84 cell | Growth inhibition assay | Inhibition of human LAMA-84 cell growth in a cell viability assay, IC50=13.6742 μM | SANGER | ||
| LB1047-RCC cell | Growth inhibition assay | Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50=28.3883 μM | SANGER | ||
| LB2241-RCC cell | Growth inhibition assay | Inhibition of human LB2241-RCC cell growth in a cell viability assay, IC50=10.5536 μM | SANGER | ||
| LB2518-MEL cell | Growth inhibition assay | Inhibition of human LB2518-MEL cell growth in a cell viability assay, IC50=1.71496μM | SANGER | ||
| LB831-BLC cell | Growth inhibition assay | Inhibition of human LB831-BLC cell growth in a cell viability assay, IC50=11.1726 μM | SANGER | ||
| LB996-RCC cell | Growth inhibition assay | Inhibition of human LB996-RCC cell growth in a cell viability assay, IC50=12.7431 μM | SANGER | ||
| LC4-1 cell | Growth inhibition assay | Inhibition of human LC4-1 cell growth in a cell viability assay, IC50=32.8341 μM | SANGER | ||
| LOUCY cell | Growth inhibition assay | Inhibition of human LOUCY cell growth in a cell viability assay, IC50=1.15276 μM | SANGER | ||
| LOXIMVI cell | Growth inhibition assay | Inhibition of human LOXIMVI cell growth in a cell viability assay, IC50=30.2122 μM | SANGER | ||
| LS-123 cell | Growth inhibition assay | Inhibition of human LS-123 cell growth in a cell viability assay, IC50=39.2258 μM | SANGER | ||
| LU-134-A cell | Growth inhibition assay | Inhibition of human LU-134-A cell growth in a cell viability assay, IC50=7.14068 μM | SANGER | ||
| LU-139 cell | Growth inhibition assay | Inhibition of human LU-139 cell growth in a cell viability assay, IC50=22.218 μM | SANGER | ||
| LXF-289 cell | Growth inhibition assay | Inhibition of human LXF-289 cell growth in a cell viability assay, IC50=17.4351μM | SANGER | ||
| MC116 cell | Growth inhibition assay | Inhibition of human MC116 cell growth in a cell viability assay, IC50=45.0841 μM | SANGER | ||
| MDA-MB-134-VI cell | Growth inhibition assay | Inhibition of human MDA-MB-134-VI cell growth in a cell viability assay, IC50=39.2486 μM | SANGER | ||
| MFH-ino cell | Growth inhibition assay | Inhibition of human MFH-ino cell growth in a cell viability assay, IC50=0.64383 μM | SANGER | ||
| MHH-NB-11 cell | Growth inhibition assay | Inhibition of human MHH-NB-11 cell growth in a cell viability assay, IC50=0.0669 μM | SANGER | ||
| ML-2 cell | Growth inhibition assay | Inhibition of human ML-2 cell growth in a cell viability assay, IC50=3.40304 μM | SANGER | ||
| MOLT-13 cell | Growth inhibition assay | Inhibition of human MOLT-13 cell growth in a cell viability assay, IC50=4.43653 μM | SANGER | ||
| MOLT-16 cell | Growth inhibition assay | Inhibition of human MOLT-16 cell growth in a cell viability assay, IC50=4.11163 μM | SANGER | ||
| MOLT-4 cell | Growth inhibition assay | Inhibition of human MOLT-4 cell growth in a cell viability assay, IC50=14.4124 μM | SANGER | ||
| MPP-89 cell | Growth inhibition assay | Inhibition of human MPP-89 cell growth in a cell viability assay, IC50=1.25922 μM | SANGER | ||
| MRK-nu-1 cell | Growth inhibition assay | Inhibition of human MRK-nu-1 cell growth in a cell viability assay, IC50=0.57572 μM | SANGER | ||
| MSTO-211H cell | Growth inhibition assay | Inhibition of human MSTO-211H cell growth in a cell viability assay, IC50=12.869 μM | SANGER | ||
| MV-4-11 cell | Growth inhibition assay | Inhibition of human MV-4-11 cell growth in a cell viability assay, IC50=0.13915 μM | SANGER | ||
| NALM-6 cell | Growth inhibition assay | Inhibition of human NALM-6 cell growth in a cell viability assay, IC50=1.56109 μM | SANGER | ||
| NB1 cell | Growth inhibition assay | Inhibition of human NB1 cell growth in a cell viability assay, IC50=3.84369 μM | SANGER | ||
| NB10 cell | Growth inhibition assay | Inhibition of human NB10 cell growth in a cell viability assay, IC50=0.13915 μM | SANGER | ||
| NB12 cell | Growth inhibition assay | Inhibition of human NB12 cell growth in a cell viability assay, IC50=16.5656 μM | SANGER | ||
| NB13 cell | Growth inhibition assay | Inhibition of human NB13 cell growth in a cell viability assay, IC50=2.31278 μM | SANGER | ||
| NB17 cell | Growth inhibition assay | Inhibition of human NB17 cell growth in a cell viability assay, IC50=3.58051 μM | SANGER | ||
| NB6 cell | Growth inhibition assay | Inhibition of human NB6 cell growth in a cell viability assay, IC50=0.59114 μM | SANGER | ||
| NCCIT cell | Growth inhibition assay | Inhibition of human NCCIT cell growth in a cell viability assay, IC50=41.8453 μM | SANGER | ||
| NCI-H1155 cell | Growth inhibition assay | Inhibition of human NCI-H1155 cell growth in a cell viability assay, IC50=14.3408 μM | SANGER | ||
| NCI-H1304 cell | Growth inhibition assay | Inhibition of human NCI-H1304 cell growth in a cell viability assay, IC50=11.8982 μM | SANGER | ||
| NCI-H1355 cell | Growth inhibition assay | Inhibition of human NCI-H1355 cell growth in a cell viability assay, IC50=4.9411 μM | SANGER | ||
| NCI-H1395 cell | Growth inhibition assay | Inhibition of human NCI-H1395 cell growth in a cell viability assay, IC50=22.8795 μM | SANGER | ||
| NCI-H1417 cell | Growth inhibition assay | Inhibition of human NCI-H1417 cell growth in a cell viability assay, IC50=5.67522 μM | SANGER | ||
| NCI-H1436 cell | Growth inhibition assay | Inhibition of human NCI-H1436 cell growth in a cell viability assay, IC50=3.84101 μM | SANGER | ||
| NTERA-S-cl-D1 cell | Growth inhibition assay | Inhibition of human NTERA-S-cl-D1 cell growth in a cell viability assay, IC50=12.8935 μM | SANGER | ||
| JiyoyeP-2003 cell | Growth inhibition assay | Inhibition of human JiyoyeP-2003 cell growth in a cell viability assay, IC50=36.6284 μM | SANGER | ||
| 点击查看更多细胞系数据 | |||||
生物活性
| 产品描述 | GSK269962A HCl是选择性的ROCK(Rho-associated protein kinase)抑制剂，对ROCK1和ROCK2的IC50分别为1.6 nM和4 nM。 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 靶点 |
|
| 体外研究(In Vitro) | ||||
| 体外研究活性 | GSK269962A在人类平滑肌中，完全阻断血管紧张肽Ⅱ诱导的肌动蛋白张力丝的形成。这一抑制现象始于约1 μM GSK269962A。GSK269962A在预束紧的大鼠动脉（组织浴/组织培养）中诱导血管舒张，IC50为35 nM。GSK269962A所诱导的舒张是可逆的。GSK269962A在巨噬细胞中抑制IL-6 mRNA的转录、减少LPS诱导的IL-6和TNF-α蛋白的产生[1]。 | |||
|---|---|---|---|---|
| 细胞实验 | 细胞系 | 平滑肌细胞 | ||
| 浓度 | 3 μM | |||
| 孵育时间 | 150 min | |||
| 方法 | 对人类平滑肌细胞进行血清饥饿处理（细胞于盖玻片上生长，达到50%融合时，血清饥饿处理过夜），用AngⅡ（100 nM）对其进行刺激2小时。在刺激前30分钟，加入ROCK抑制剂（3 μM SB-772077-B或GSK269962A），刺激后将细胞进行固定，用鬼笔环肽对肌动蛋白进行染色。 | |||
| 体内研究(In Vivo) | ||
| 体内研究活性 | 自发性高血压大鼠口服GSK269962A将降低体循环血压，血压的减少非常迅速并显著。在口服给药后约2小时，其降血压作用达到峰值。血压的减少伴随着急性、剂量依赖性的心率增加，这可能是压力反射机制的激活[1]。用10 mg/kg的GSK 269962抑制ROCK在大鼠内能依次地引起排尿量、排尿后残余尿、容量阈值、泌尿效率、ICI(intercontraction interval)、膀胱顺应性、VTNVC的升高，而对心率、收缩压、平均血压、舒张压没有影响[2]。 | |
|---|---|---|
| 动物实验 | Animal Models | Wistar雌性大鼠 |
| Dosages | 5 或 10 mg/kg | |
| Administration | 动脉注射 | |
|
化学信息&溶解度
| 分子量 | 607.06 | 分子式 | C29H30N8O5.HCl |
| CAS号 | 2095432-71-4 | SDF | Download GSK269962A HCl SDF |
| Smiles | CCN1C2=CC(=NC=C2N=C1C3=NON=C3N)OC4=CC=CC(=C4)NC(=O)C5=CC=C(C=C5)OCCN6CCOCC6.Cl | ||
| 储存条件(自收到货起) | |||
|
体内溶解配方 现配现用，请按从左到右的顺序依次添加，澄清后再加入下一溶剂 |
动物体内配方计算器 | |||||
实验计算
动物体内配方计算器（澄清溶液）
第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）
mg/kg
g
μL
只
第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）
% DMSO
%
% Tween 80
% ddH2O
%DMSO
%
计算结果：
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于μL DMSO溶液（母液浓度mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；
体内配方配制方法：取μL DMSO母液，加入μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入μL ddH2O，混匀澄清。
体内配方配制方法：取μL DMSO母液，加入μL Corn oil，混匀澄清。
注意：1. 首先保证母液是澄清的；
2.一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
技术支持
在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。
如果有其他问题，请给我们留言。
* 必填项
Tags: buy GSK269962A HCl | GSK269962A HCl supplier | purchase GSK269962A HCl | GSK269962A HCl cost | GSK269962A HCl manufacturer | order GSK269962A HCl | GSK269962A HCl distributor
